Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Melior Discovery Inc.

Latest From Melior Discovery Inc.

On The Move: Who’s Going Where In Biopharma And Medtech Start-Ups

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

The Value of Drug Repositioning: Longer Patent Life

According to Gene Logic, there's value in failed Phase II candidates-so long as safety's not the problem. The company claims that repositioning a compound in a new indication creates an asset worth 27% more, in net present value terms, than an equivalent in-licensed drug.

BioPharmaceutical Strategy

A New Approach to Repurposing: Ditch the Hypotheses

By pulling together 35 publicly available gold-standard animal models, Melior Discovery has built a stable of what it calls privileged compounds. The repurposing company augments its VC funds with service deals and is aiming to progress its lead compound into Phase I studies in 2007.

BioPharmaceutical Strategy

Selected Start-Ups (5/06)

In Vivo briefly summarizes the technologies of these recently founded companies: Carbylan BioSurgery, KAHR Pharmaceuticals, Melior Discovery, Myomo, Nanonucleant, Pelican Life Sciences.

See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools